Clinical Trials Browser

Phase 3 × Has results × lorlatinib × Clear all

NCT03052608 2025-11-25

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

Phase 3 Active not recruiting

296 enrolled 28 charts 1 FDA

Carcinoma, Non-Small-Cell Lung